Skip to main content
INCR
NASDAQ Life Sciences

InterCure Secures $7M Private Placement, CEO Participates, to Fund Growth

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$0.969
Mkt Cap
$55.006M
52W Low
$0.68
52W High
$1.77
52W Position info
42% above low
Off High info
45% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

INCR sits 42% above its 52-week low of $0.68 on light trading volume (0.3× avg).

Summary

InterCure Ltd. has secured $7 million in a private placement, with potential for up to $18.6 million, to fund its recovery and global expansion, including participation from its CEO and leading hedge funds.


Key Events · Financing and Capital Events · INCR

  • Secured Significant Financing

    InterCure obtained $7 million in a private placement, with the potential to reach $18.6 million if warrants are fully exercised. This represents a substantial capital injection relative to the company's market capitalization.

  • Insider and Institutional Confidence

    The private placement includes participation from CEO Alexander Rabinovich (subject to shareholder approval) and leading pharma-focused hedge funds, indicating strong belief in the company's prospects.

  • Favorable Pricing

    Shares were issued at NIS 2.75 (approximately $0.94), a premium to the Tel Aviv Stock Exchange closing price on the determining date, with warrants exercisable at a further premium.

  • Strategic Use of Proceeds

    Funds will support the recovery and expansion of the Nir Oz facility, meet growing demand in Israel and international markets, and accelerate global expansion, particularly in Germany and regulated U.S. medical cannabis markets.


Analysis · INCR · Life Sciences

This significant capital raise provides InterCure with crucial funding for its strategic growth initiatives, including the expansion of its Nir Oz facility and international market penetration. The participation of the CEO and institutional investors, coupled with the premium pricing of the shares relative to the TASE, signals strong confidence in the company's future, especially important given its recent Nasdaq minimum bid price non-compliance notice. The funding strengthens the balance sheet and supports the company's path to sustainable growth.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, INCR was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55M. The 52-week trading range was $0.68 to $1.77. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

INCR - Latest Insights

INCR
Sep 08, 2026, 4:13 PM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $5.39
Real-time Price: $3.49 info
Change: -$1.90 (-35%) info
Market Cap: $45.276M info
INCR
Aug 27, 2026, 11:38 AM EDT
Filing Type: 6-K/A
Importance Score:
7
Price at Filing: $5.74
Real-time Price: $3.49 info
Change: -$2.25 (-39%) info
Market Cap: $45.276M info
INCR
Aug 26, 2026, 4:06 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $5.85
Real-time Price: $3.49 info
Change: -$2.36 (-40%) info
Market Cap: $45.276M info
INCR
Aug 24, 2026, 7:05 AM EDT
Filing Type: 6-K
Importance Score:
8
Price at Filing: $1.15
Real-time Price: $3.49 info
Change: Reverse Stock Split info
Market Cap: $45.276M info
INCR
Aug 24, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.15
Real-time Price: $3.49 info
Change: Reverse Stock Split info
Market Cap: $45.276M info